Cargando…

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terada, Naoki, Akamatsu, Shusuke, Kobayashi, Takashi, Inoue, Takahiro, Ogawa, Osamu, Antonarakis, Emmanuel S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524249/ https://www.ncbi.nlm.nih.gov/pubmed/28794807 http://dx.doi.org/10.1177/1758834017719215

Ejemplares similares

Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models
por: Nagai, Takahiro, et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
por: Sumiyoshi, Takayuki, et al.
Publicado: (2019)

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation
por: Aizawa, Rihito, et al.
Publicado: (2019)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer
por: Sato, Genki Edward, et al.
Publicado: (2020)

Narrative review of challenges in the management of advanced neuroendocrine prostate cancer
por: Okasho, Kosuke, et al.
Publicado: (2021)

Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer
por: Miyazaki, Yu, et al.
Publicado: (2019)

High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer
por: Li, Xin, et al.
Publicado: (2021)

A narrative review of urinary phospholipids: from biochemical aspect towards clinical application
por: Li, Xin, et al.
Publicado: (2021)

A 45,X/46,XY Male with Orchidopexy Diagnosed with Mixed Germ Cell Tumor After 21-year Follow-up
por: Kubota, Masashi, et al.
Publicado: (2017)

Ten‐year outcomes of whole‐pelvic intensity‐modulated radiation therapy for prostate cancer with regional lymph node metastasis
por: Nakamura, Kiyonao, et al.
Publicado: (2022)

Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
por: Aizawa, Rihito, et al.
Publicado: (2022)

The Expression Profile of Phosphatidylinositol in High Spatial Resolution Imaging Mass Spectrometry as a Potential Biomarker for Prostate Cancer
por: Goto, Takayuki, et al.
Publicado: (2014)

Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Takamori, Hajime, et al.
Publicado: (2020)

Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Up‐regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy
por: Miyazaki, Yu, et al.
Publicado: (2022)

Data processing on a comparative evaluation of the extraction and analysis procedures for urinary phospholipid and lysophospholipid using MALDI-TOF/MS
por: Li, Xin, et al.
Publicado: (2019)

Initial evaluation of PET/CT with (18)F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients
por: Saga, Tsuneo, et al.
Publicado: (2019)

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13
por: Okasho, Kosuke, et al.
Publicado: (2021)

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer
por: Suzman, Daniel L., et al.
Publicado: (2015)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

The C-Terminal Fragment of Prostate-Specific Antigen, a 2331 Da Peptide, as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer
por: Nakayama, Kenji, et al.
Publicado: (2014)

Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
por: Sakamoto, Hiromasa, et al.
Publicado: (2020)

Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy
por: Akamatsu, Shusuke, et al.
Publicado: (2022)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
por: Bastos, Diogo A, et al.
Publicado: (2016)

Nutrition, dietary interventions and prostate cancer: the latest evidence
por: Lin, Pao-Hwa, et al.
Publicado: (2015)

Spotlight on prostate cancer: the latest evidence and current controversies
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
por: Inoue, Takahiro, et al.
Publicado: (2011)

Reproducibility, Performance, and Clinical Utility of a Genetic Risk Prediction Model for Prostate Cancer in Japanese
por: Akamatsu, Shusuke, et al.
Publicado: (2012)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
por: Shimizu, Kosuke, et al.
Publicado: (2022)

Treatment of diverticular disease: an update on latest evidence and clinical implications
por: Carabotti, Marilia, et al.
Publicado: (2018)

Targeted therapy of brain metastases: latest evidence and clinical implications
por: Di Lorenzo, Rodica, et al.
Publicado: (2017)

Adding ezetimibe to statin therapy: latest evidence and clinical implications
por: Vavlukis, Marija, et al.
Publicado: (2018)

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
por: Santoni, Matteo, et al.
Publicado: (2018)

Managing hyponatremia in lung cancer: latest evidence and clinical implications
por: Fiordoliva, Ilaria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1lmhgk872q4gki0o0ut4scg99m